Advances in the research of HIV-1 envelope glycoprotein gp120 inhibitors / 药学学报
Acta Pharmaceutica Sinica
; (12): 616-628, 2023.
Article
em Zh
| WPRIM
| ID: wpr-965629
Biblioteca responsável:
WPRO
ABSTRACT
From the process of human immunodeficiency virus-1 (HIV-1) invading cells, the combination of gp120 and CD4 is the first step for HIV-1 to invade cells. Interfering with this process can prevent HIV from recognizing target cells and inhibit virus replication. Therefore, HIV-1 gp120 is an important part of the HIV-1 life cycle. Fostesavir, a phosphatate prodrug derived from the gp120 inhibitor BMS-626529 modified by the prodrug strategy, was approved for the treatment of adult patients with multidrug resistant HIV-1 infection by the US FDA and the European Medicines Agency in 2020 and 2021, respectively. In this review, we focus on the research progress of small molecule inhibitors targeting the interaction of gp120-CD4 from the perspective of medicinal chemistry, in order to provide reference for the subsequent research of gp120 inhibitors.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Acta Pharmaceutica Sinica
Ano de publicação:
2023
Tipo de documento:
Article